Indivior is pioneering the development and discovery of non-opioid treatment strategies for OUD, as well as exploring new therapies to potentially address the needs of people suffering from alcohol, stimulant and cannabis use disorders.
Indivior’s R&D has led to a range of daily and monthly treatment options for patients with moderate-to -severe opioid use disorder. We also developed a monthly treatment option for the treatment of schizophrenia in adult patients.
Indivior’s quarterly R&D and pipeline update can be found here.
Compound Name
Preclinical
Phase 1
Phase 2
Phase 3
Regulatory Approval or Review
-
Treatment for Substance Use Disorder
INDV-10001 - GABA-B Positive Allosteric Modulator
-
Treatment for Substance Use Disorder
INDV-20002 - Selective Orexin-1 Receptor Antagonist
-
Treatment for Cannabis Use Disorder
AEF01173 - Synthetic Signaling Specific inhibitor (SSi) of the Cannabinoid Type 1 (CB1) Receptor
-
Treatment for Opioid Use Disorder
RBP-6000 - Buprenorphine XR injection for Subcutaneous Use
-
Treatment for Schizophrenia
RBP-70004 - Risperidone XR injection for Subcutaneous Use
-
Treatment for Opioid Use Disorder
Buprenorphine/ Naloxone Sublingual Film
-
Treatment for Opioid Use Disorder
Buprenorphine/ Naloxone Sublingual Tablet
-
Treatment for Opioid Use Disorder
Buprenorphine Sublingual Tablet
-
Treatment for Substance Use Disorder
INDV-10001 - GABA-B Positive Allosteric Modulator
-
Treatment for Substance Use Disorder
INDV-20002 - Selective Orexin-1 Receptor Antagonist
-
Treatment for Cannabis Use Disorder
AEF01173 - Synthetic Signaling Specific inhibitor (SSi) of the Cannabinoid Type 1 (CB1) Receptor
-
Treatment for Opioid Use Disorder
RBP-6000 - Buprenorphine XR injection for Subcutaneous Use
-
Treatment for Schizophrenia
RBP-70004 - Risperidone XR injection for Subcutaneous Use
-
Treatment for Opioid Use Disorder
Buprenorphine/ Naloxone Sublingual Film
-
Treatment for Opioid Use Disorder
Buprenorphine/ Naloxone Sublingual Tablet
-
Treatment for Opioid Use Disorder
Buprenorphine Sublingual Tablet
Pipeline Disclaimer: The information included on this site reflects Indivior’s research and development pipeline and is not intended for promotional purposes. Information is current as of July 30, 2021.